J.P. Bilezikian, A.A. Khan, S.J. Silverberg, G.E.-H. Fuleihan, C. Marcocci, S. Minisola, N. Perrier, A. Sitges-Serra, R.V. Thakker, G. Guyatt, M. Mannstadt, J.T. Potts, B.L. Clarke, M.L. Brandi. On behalf of the International Workshop on Primary Hyperparathyroidism Evaluation and Management of Primary Hyperparathyroidism: Summary Statement and Guidelines from the Fifth International Workshop 2022. https://doi.org/10.1002/jbmr.4677

J. Bollerslev, C. Schalin-Jäntti, L. Rejnmark, H. Siggelkow, H. Morreau, R. Thakker, A. Sitges-Serra, F. Cetani, C. Marcocci, Management of endocrine disease: Unmet therapeutic, educational and scientific needs in parathyroid disorders. Eur. J. Endocrinol. 181(3), P1–P19 (2019). https://doi.org/10.1530/EJE-19-0316

Article  CAS  PubMed  PubMed Central  Google Scholar 

S. Minisola, A. Arnold, Z. Belaya, M.L. Brandi, B.L. Clarke, F.M. Hannan, L.C. Hofbauer, K.L. Insogna, A. Lacroix, U. Liberman, A. Palermo, J. Pepe, R. Rizzoli, R. Wermers, R.V. Thakker, Epidemiology, pathophysiology, and genetics of primary hyperparathyroidism. J. Bone Min. Res. 2022 Aug. https://doi.org/10.1002/jbmr.4665

L.J. Melton 3rd, Epidemiology of primary hyperparathyroidism. J. Bone Min. Res. 6(Suppl 2), S25–S30 (1991). https://doi.org/10.1002/jbmr.5650061409

Article  Google Scholar 

M.D. Walker, S.J. Silverberg, Primary hyperparathyroidism. Nat. Rev. Endocrinol. 14(2), 115–125 (2018). https://doi.org/10.1038/nrendo.2017.104

Article  CAS  PubMed  Google Scholar 

E. Mamedova, N. Mokrysheva, E. Vasilyev, V. Petrov, E. Pigarova, S. Kuznetsov, N. Kuznetsov, L. Rozhinskaya, G. Melnichenko, I. Dedov, A. Tiulpakov, Primary hyperparathyroidism in young patients in Russia: high frequency of hyperparathyroidism-jaw tumor syndrome. Endocr. Connect 6(Nov 8), 557–565 (2017). https://doi.org/10.1530/EC-17-0126

Article  CAS  PubMed  PubMed Central  Google Scholar 

A.E. Stephen, M. Mannstadt, R.A. Hodin, Indications for surgical management of hyperparathyroidism: a review. JAMA Surg. 152(9), 878–882 (2017). https://doi.org/10.1001/jamasurg.2017.1721

Article  PubMed  Google Scholar 

J. Bollerslev, L. Rejnmark, A. Zahn, A. Heck, N.M. Appelman-Dijkstra, L. Cardoso, F.M. Hannan, F. Cetani, T. Sikjær, A.M. Formenti, S. Björnsdottir, C. Schalin-Jantti, Z. Belaya, F.W. Gibb, B. Lapauw, K. Amrein, C. Wicke, C. Grasemann, M. Krebs, E.M. Ryhänen, O. Makay, S. Minisola, S. Gaujoux, J.P. Bertocchio, Z.K. Hassan-Smith, A. Linglart, E.M. Winter, M. Kollmann, H.G. Zmierczak, E. Tsourdi, S. Pilz, H. Siggelkow, N.J. Gittoes, C. Marcocci, P. Kamenicky, European Expert Consensus on Practical Management of Specific Aspects of Parathyroid Disorders in Adults and in Pregnancy: Recommendations of the ESE Educational Program of Parathyroid Disorders. Eur. J. Endocrinol. 2021 Dec:EJE-21-1044.R1. https://doi.org/10.1530/EJE-21-1044

J.S. Leere, J. Karmisholt, M. Robaczyk, P. Vestergaard, Contemporary medical management of primary hyperparathyroidism: a systematic review. Front. Endocrinol. 8, (2017). https://doi.org/10.3389/fendo.2017.00079

L. Wang, L. Quarles, R. Spurney, Unmasking the osteoinductive effects of a G-protein-coupled receptor (GPCR) kinase (GRK) inhibitor by treatment with PTH (1–34). J. Bone Min. Res. 19(10), 1661–1670 (2004). https://doi.org/10.1359/JBMR.040708

Article  CAS  Google Scholar 

Y. Ma, R. Cain, D. Halladay, X. Yang, Q. Zeng, R. Miles, S. Chandrasekhar, T. Martin, J. Onyia, Catabolic effects of continuous human PTH (1–38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and geneassociated bone formation. Endocrinology 142(9), 4047–4054 (2001). https://doi.org/10.1210/endo.142.9.8356

Article  CAS  PubMed  Google Scholar 

Y. Ueno, T. Shinki, Y. Nagai, H. Murayama, K. Fujii, T. Suda, In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. J. Cell Biochem 90(Oct 2), 267–277 (2003). https://doi.org/10.1002/jcb.10623

Article  CAS  PubMed  Google Scholar 

A.D. Anastasilakis, D.G. Goulis, S.A. Polyzos, S. Gerou, V. Pavlidou, G. Koukoulis, A. Avramidis, Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-kB ligand levels in women with established osteoporosis treated with teriparatide. Eur. J. Endocrinol. 158(3), 411–415 (2008). https://doi.org/10.1530/EJE-07-0528

Article  CAS  PubMed  Google Scholar 

L. Stilgren, E. Rettmer, E. Eriksen, L. Hegedus, H. Beck-Nielsen, B. Abrahamsen, Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kb ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with. Bone Metab. Bone 35(Jul 1), 256–265 (2004). https://doi.org/10.1016/j.bone.2004.03.012

Article  CAS  Google Scholar 

S. Khosla, L.C. Hofbauer, Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 5(11), 898–907 (2017). https://doi.org/10.1016/S2213-8587(17)30188-2

Article  PubMed  PubMed Central  Google Scholar 

S.R. Cummings, J. San Martin, M.R. McClung, E.S. Siris, R. Eastell, I.R. Reid, P. Delmas, H.B. Zoog, M. Austin, A. Wang, S. Kutilek, S. Adami, J. Zanchetta, C. Libanati, S. Siddhanti, C. Christiansen, Freedom Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361(Aug 8), 756–765 (2009). https://doi.org/10.1056/NEJMoa0809493

Article  CAS  PubMed  Google Scholar 

S. Papapoulos, K. Lippuner, C. Roux, C.J. Lin, D.L. Kendler, E.M. Lewiecki, M.L. Brandi, E. Czerwiński, E. Franek, P. Lakatos, C. Mautalen, S. Minisola, J.Y. Reginster, S. Jensen, N.S. Daizadeh, A. Wang, M. Gavin, C. Libanati, R.B. Wagman, H.G. Bone, The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos. Int. 26(12), 2773–2783 (2015). https://doi.org/10.1007/s00198-015-3234-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

I.R. Reid, P.D. Miller, J.P. Brown, D.L. Kendler, A. Fahrleitner-Pammer, I. Valter, K. Maasalu, M.A. Bolognese, G. Woodson, H. Bone, B. Ding, R.B. Wagman, J. San Martin, M.S. Ominsky, D.W. Dempster, Denosumab phase 3 bone Histology Study Group. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J. Bone Min. Res. 25(10), 2256–2265 (2010). https://doi.org/10.1002/jbmr.149

Article  CAS  Google Scholar 

Z.E. Belaya, J.P. Bilezikian, O.B. Ershova, O.M. Lesnyak, L.A. Marchenkova, S.S. Rodionova, L.Y. Rozhinskaya, N.V. Toroptsova, S.V. Yureneva, Long-term treatment options for postmenopausal osteoporosis: results of recent clinical studies of Denosumab. Osteoporos. Bone Dis. 21(1), 17–22 (2018). https://doi.org/10.14341/osteo9760

Article  Google Scholar 

E. Tsourdi, M.C. Zillikens, C. Meier, J.J. Body, E. Gonzalez Rodriguez, A.D. Anastasilakis, B. Abrahamsen, E. McCloskey, L.C. Hofbauer, N. Guañabens, B. Obermayer-Pietsch, S.H. Ralston, R. Eastell, J. Pepe, A. Palermo, B. Langdahl, Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J. Clin. Endocrinol. Metab. 2020 Oct:dgaa756. https://doi.org/10.1210/clinem/dgaa756

C. Beaudoin, S. Jean, L. Bessette, L.G. Ste-Marie, L. Moore, J.P. Brown, Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis. Osteoporos. Int. 2016 27(9), 2835–2844 (2016). https://doi.org/10.1007/s00198-016-3607-6

Article  CAS  Google Scholar 

E. Seeman, P.D. Delmas, D.A. Hanley, D. Sellmeyer, A.M. Cheung, E. Shane, A. Kearns, T. Thomas, S.K. Boyd, S. Boutroy, C. Bogado, S. Majumdar, M. Fan, C. Libanati, J. Zanchetta, Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J. Bone Min. Res. 25(8), 1886–1894 (2010). https://doi.org/10.1002/jbmr.81

Article  Google Scholar 

J.P. Brown, C. Roux, P.R. Ho, M.A. Bolognese, J. Hall, H.G. Bone, S. Bonnick, J.P. van den Bergh, I. Ferreira, P. Dakin, R.B. Wagman, C. Recknor, Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate. Osteoporos. Int. 25(7), 1953–1961 (2014). https://doi.org/10.1007/s00198-014-2692-7

Article  CAS  PubMed  Google Scholar 

H. Lyu, B. Jundi, C. Xu, S.K. Tedeschi, K. Yoshida, S. Zhao, S.U. Nigwekar, B.Z. Leder, D.H. Solomon, Comparison of denosumab vs. bisphosphonates in osteoporosis patients: a meta-analysis of randomized controlled trials. J. Clin. Endocrinol. Metab. 104(5), 1753–1765 (2019). https://doi.org/10.1210/jc.2018-02236

Article  PubMed  Google Scholar 

J.S. Leere, J. Karmisholt, M. Robaczyk, S. Lykkeboe, A. Handberg, E. Steinkohl, J. Brøndum Frøkjær, P. Vestergaard, Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 8(5), 407–417 (2020). https://doi.org/10.1016/S2213-8587(20)30063-2

Article  CAS  PubMed  Google Scholar 

H.G. Bone, R.B. Wagman, M.L. Brandi, J.P. Brown, R. Chapurlat, S.R. Cummings, E. Czerwiński, A. Fahrleitner-Pammer, D.L. Kendler, K. Lippuner, J.Y. Reginster, C. Roux, J. Malouf, M.N. Bradley, N.S. Daizadeh, A. Wang, P. Dakin, N. Pannacciulli, D.W. Dempster, S. Papapoulos, 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the 2017 phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 5(7):513–523. https://doi.org/10.1016/S2213-8587(17)30138-9

A. Broadwell, A. Chines, P.R. Ebeling, E. Franek, S. Huang, S. Smith, D. Kendler, O. Messina, P.D. Miller, Denosumab safety and efficacy among participants in the freedom extension study with mild to moderate chronic kidney disease. J. Clin. Endocrinol. Metab. 106(Jan 2), 397–409 (2021). https://doi.org/10.1210/clinem/dgaa851

Article  PubMed  Google Scholar 

ЕА Pigarova, L.Y. Rozhinskaya, Z.E. Belaya, L.K. Dzeranova, T.L. Karonova, A.V. Ilyin, G.A. Melnichenko, I.I. Dedov, Russian association of endocrinologists recommendations for diagnosis, treatment and prevention of vitamin D deficiency in adults. Probl. Endocrinol. 62(4), 60–84 (2016). https://doi.org/10.14341/probl201662460-84

Article  Google Scholar 

M. Ketteler, G.A. Block, P. Evenepoel, M. Fukagawa, C.A. Herzog, L. McCann, S.M. Moe, R. Shroff, M.A. Tonelli, N.D. Toussaint, M.G. Vervloet, M.B. Leonard, Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int. 92(Jul 1), 26–36 (2017). https://doi.org/10.1016/j.kint.2017.04.006

Article  PubMed  Google Scholar 

C. Chiang, The use of bone turnover markers in chronic kidney disease-mineral and bone disorders. Nephrol. (Carlton) 22(Mar Suppl 2), 11–13 (2017). https://doi.org/10.1111/nep.13014. PMID: 28429547

Article  CAS  Google Scholar 

S.A. Jamal, O. Ljunggren, C. Stehman-Breen, S.R. Cummings, M.R. McClung, S. Goemaere, P.R. Ebeling, E. Franek, Y.C. Yang, O.I. Egbuna, S. Boonen, P.D. Miller, Effects of denosumab on fracture and bone mineral density by level of kidney function. J. Bone Min. Res. 26(8), 1829–1835 (2011). https://doi.org/10.1002/jbmr.403

Article  CAS  Google Scholar 

C. Eller-Vainicher, S. Palmieri, E. Cairoli, G. Goggi, A. Scillitani, M. Arosio, A. Falchetti, I. Chiodini, Protective effect of denosumab on bone in older women with primary hyperparathyroidism. J. Am. Geriatr. Soc. 66(3), 518–524 (2018). https://doi.org/10.1111/jgs.15250

Article  PubMed  Google Scholar 

L.Y. Rozhinskaya, S.A. Gronskaya, E.O. Mamedova, Z.E. Belaya, G.A. Melnichenko, The comparative efficiency of denosumab treatment in patients with postmenopausal osteoporosis, primary hyperparathyroidism and glucocorticoid-induced osteoporosis in real clinical practice. Osteoporos. bone Dis. 23(1), 4–13 (2020). https://doi.org/10.14341/osteo12415

Article  Google Scholar 

J. Wu, Q. Zhang, G. Yan, X. Jin, Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis. J. Orthop. Surg. Res. 13(Aug), 194 (2018). https://doi.org/10.1186/s13018-018-0865-3

Article  PubMed  PubMed Central  Google Scholar 

R.M. Zebaze, A. Ghasem-Zadeh, A. Bohte, S. Iuliano-Burns, M. Mirams, R.I. Price, E.J. Mackie, E. Seeman, Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet 375(May 9727), 1729–1736 (2010). https://doi.org/10.1016/S0140-6736(10)60320-0

Article  PubMed  Google Scholar 

H. Matsuno, Assessment of distal radius bone mineral density in osteoporosis patients receiving denosumab, including those with rheumatoid arthritis and those receiving oral glucocorticoids. Drugs R. D. 16(Dec), 347–353 (2016). https://doi.org/10.1007/s40268-016-0146-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

D. Segula, T. Nikolova, E. Marks, L. Ranganath, V. Mishra, Long term outcome of bisphosphonate therapy in patients with primary hyperparathyroidism. Int. J. Clin. Med. 5(5), 829–835 (2017). https://doi.org/10.4236/ijcm.2014.514111

Article  CAS  Google Scholar